Drugs Begining With“a”
For the treatment of HIV-1 infection, in combination with other antiretroviral agents.
For palliative treatment of advanced prostate cancer.
For the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children.
Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and
in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Investigated for use/treatment in rheumatoid arthritis and systemic lupus erythematosus.
Investigated for use/treatment in Alzheimer's disease, Attention Deficit/Hyperactivity Disorder (ADHD), and Schizophrenia and schizoaffective disorders.
Investigated for use/treatment in lung cancer and lymphoma (unspecified).
Investigated for use/treatment in lymphoma (unspecified), melanoma, and solid tumors.
Investigated for use/treatment in neurologic disorders.
Investigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.
Investigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.